Hans90 schreef op 4 februari 2020 20:38:
Ik heb even naar de Japanse partner Nichirei gekeken. Wat me opvalt is dat hun biotech afdeling 45 MEur omzet draait en onder "other" valt in hun corporate resultaten/presentaties (1% van hun totale omzet). Hun Q/A van kwartaal bevat volgende verwijzingen naar de biotech afdeling. Wat is jullie idee van Nichirei als partner?
Q. President Okushi, it’s now been six months since you assumed your present roll. Would you
summarize the response and current issues?
A.Earnings have been mostly in line with plan, driven by the Processed Foods and Logistics
segments. However, in terms of enhancing the collective strengths of the corporate group, the
Marine Products, Meat and Poultry, and bioscience business in the Other segment have
struggled during the current term.
The food business in Japan is changing substantively. We will utilize our advantage in production,
while also strengthening our technology development and planning/solutions capabilities, to
further enhance our customer responsiveness. Outside Japan, the Asian foods market in the
United States is growing. We will delve deeper and expand in this category, and increase our
For the Marine Products and Meat and Poultry segments, we will shift from quantitative
expansion, and increase profitability by raising the level of processing, and providing added
Q. What are the reasons for the downward revision in the operating income forecast for the
A. The downward revision is due mainly to the bioscience business. Sales of molecular diagnostic
reagents and rapid diagnostic reagents fell short of initial plan, and we incurred temporary
expenses including startup costs for a new R&D center, and acquisition-related expenditures in the